Maria Garzo

Maria Garzo

Auto-generated profile, based on publicly available information

Maria Garzo

Istituto Auxologico Italiano, IRCCS, Laboratory of Medical Cytogenetics and Molecular Genetics, 20145 Milan, Italy

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in Stem Cell Research
Verified
Journal Article
Open access
PBPatrizia Bossolasco
Patrizia Bossolasco
FSFrancesca Sassone
Francesca Sassone
VGValentina Gumina
Valentina Gumina
SPSilvia Peverelli
Silvia Peverelli
MGMaria Garzo
Maria Garzo
VSVincenzo Silani
Vincenzo Silani
Amyotrophic lateral sclerosis (ALS) is a severe neurodegenerative disease, mainly affecting the motor neurons (MNs) and without effective therapy. Drug screening is hampered by the lack of satisfactory experimental and pre-clinical models. Induced pluripotent stem cells (iPSCs) could help to define disease mechanisms and therapeutic strategies as they could be differentiated into MNs, otherwise inaccessible from living humans. In this study, given the seminal role of TDP-43 in ALS pathophysiology, MNs were obtained from peripheral blood mononuclear cells-derived iPSCs of an ALS patient carrying a p.A382T TARDBP mutation and a healthy donor. Venous samples were preferred to fibroblasts for their ease of collection and no requirement for time consuming extended cultures before experimentation. iPSCs were characterized for expression of specific markers, spontaneously differentiated into primary germ layers and, finally, into MNs. No differences were observed between the mutated ALS patient and the control MNs with most of the cells displaying a nuclear localization of the TDP-43 protein. In conclusion, we here demonstrated for the first time that human TARDBP mutated MNs can be successfully obtained exploiting the reprogramming and differentiation ability of peripheral blood cells, an easily accessible source from any patient.

27 April 2021 in Genes
Verified
Journal Article
Open access
PDF file
ICIlaria Catusi
Ilaria Catusi
MGMaria Garzo
Maria Garzo
ACAnna Paola Capra
Anna Paola Capra
SBSilvana Briuglia
Silvana Briuglia
CBChiara Baldo
Chiara Baldo
MRMaria Paola Recalcati
Maria Paola Recalcati
To date only five patients with 8p23.2-pter microdeletions manifesting a mild-to-moderate cognitive impairment and/or developmental delay, dysmorphisms and neurobehavioral issues were reported. The smallest microdeletion described by Wu in 2010 suggested a critical region (CR) of 2.1 Mb including several genes, out of which FBXO25, DLGAP2, CLN8, ARHGEF10 and MYOM2 are the main candidates. Here we present seven additional patients with 8p23.2-pter microdeletions, ranging from 71.79 kb to 4.55 Mb. The review of five previously reported and nine Decipher patients confirmed the association of the CR with a variable clinical phenotype characterized by intellectual disability/developmental delay, including language and speech delay and/or motor impairment, behavioral anomalies, autism spectrum disorder, dysmorphisms, microcephaly, fingers/toes anomalies and epilepsy. Genotype analysis allowed to narrow down the 8p23.3 candidate region which includes only DLGAP2, CLN8 and ARHGEF10 genes, accounting for the main signs of the broad clinical phenotype associated to 8p23.2-pter microdeletions. This region is more restricted compared to the previously proposed CR. Overall, our data favor the hypothesis that DLGAP2 is the actual strongest candidate for neurodevelopmental/behavioral phenotypes. Additional patients will be necessary to validate the pathogenic role of DLGAP2 and better define how the two contiguous genes, ARHGEF10 and CLN8, might contribute to the clinical phenotype.

1 February 2020 in European Journal of Medical Genetics
Verified
Journal Article
Closed access
MGMaria Garzo
Maria Garzo
ICIlaria Catusi
Ilaria Catusi
DCDaniela Maria Colombo
Daniela Maria Colombo
LGLaura De Grada
Laura De Grada
MRMaria Paola Recalcati
Maria Paola Recalcati
DGDaniela Giardino
Daniela Giardino

1 October 2019 in Stem Cell Research
Verified
Journal Article
Open access
VAValentina Alari
Valentina Alari
SRSilvia Russo
Silvia Russo
DRDavide Rovina
Davide Rovina
MGMaria Garzo
Maria Garzo
MCMilena Crippa
Milena Crippa
Lidia LarizzaLidia Larizza
Lidia Larizza
Rubinstein-Taybi syndrome (RSTS) is a neurodevelopmental disorder characterized by growth retardation, skeletal anomalies and intellectual disability, caused by heterozygous mutations in either CREBBP (RSTS1) or EP300 (RSTS2) genes. We characterized 3 iPSC lines generated by Sendai from blood of RSTS1 patients with unique non sense c.4435G > T, p.(Gly1479*), c.3474G > A, p.(Trp1158*) and missense c.4627G > T, p.(Asp1543Tyr) CREBBP mutations. All lines displayed iPSC morphology, pluripotency markers, trilineage differentiation potential, stable karyotype and specific mutations. Western-blot using a CREB-Binding Protein N-terminus antibody demonstrated the same amount of full length protein as control in the missense mutation line and reduced amount in lines with stop mutations.

18 December 2019 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
PDF file
ICIlaria Catusi
Ilaria Catusi
MRMaria Paola Recalcati
Maria Paola Recalcati
IBIlaria Bestetti
Ilaria Bestetti
MGMaria Garzo
Maria Garzo
CVChiara Valtorta
Chiara Valtorta
DGDaniela Giardino
Daniela Giardino
Background: Chromosomal microarray analysis (CMA) is nowadays widely used in the diagnostic path of patients with clinical phenotypes. However, there is no ascertained evidence to date on how to assemble single/combined clinical categories of developmental phenotypic findings to improve the array‐based detection rate.Methods: The Italian Society of Human Genetics coordinated a retrospective study which included CMA results of 5,110 Italian patients referred to 17 genetics laboratories for variable combined clinical phenotypes.Results: Non‐polymorphic copy number variants (CNVs) were identified in 1512 patients (30%) and 615 (32%) present in 552 patients (11%) were classified as pathogenic. CNVs were analysed according to type, size, inheritance pattern, distribution among chromosomes, and association to known syndromes. In addition, the evaluation of the detection rate of clinical subgroups of patients allowed to associate dysmorphisms and/or congenital malformations combined with any other single clinical sign to an increased detection rate, whereas non‐syndromic neurodevelopmental signs and non‐syndromic congenital malformations to a decreased detection rate.Conclusions: Our retrospective study resulted in confirming the high detection rate of CMA and indicated new clinical markers useful to optimize their inclusion in the diagnostic and rehabilitative path of patients with developmental phenotypes.

1 March 2018 in European Journal of Medical Genetics
Verified
Journal Article
Closed access
MRMaria Paola Recalcati
Maria Paola Recalcati
MBMaria Teresa Bonati
Maria Teresa Bonati
NBNicola Beltrami
Nicola Beltrami
LCLaura Cardarelli
Laura Cardarelli
ICIlaria Catusi
Ilaria Catusi
DGDaniela Giardino
Daniela Giardino